Zenabis Global Inc. is a licensed cannabis producer headquartered in Langley, British Columbia, operating under the symbol ZBISF on the OTC Markets. The company cultivates, processes and distributes a range of cannabis products for both medical patients and adult-use consumers. Its state-of-the-art cultivation facilities employ automated environmental controls, integrated pest management and proprietary genetics to optimize yield and consistency.
Zenabis’s product portfolio includes dried flower, pre-rolls, cannabis oils, capsules and isolates. Finished goods are packaged under the company’s own brand labels and sold through provincial distribution networks in Canada. In addition to traditional smokable formats, the company has developed formulations tailored to medical patients, including precision-dose oils and gel capsules designed for reliable pharmacokinetics and compliance with health-care regulations.
Beyond its domestic footprint, Zenabis has established strategic partnerships to export medical-grade cannabis to select international markets. The company holds Good Manufacturing Practice (GMP) certification at one of its processing plants, enabling exports to Europe under bilateral supply agreements. Zenabis’s global reach extends to jurisdictions in the European Union and Latin America, positioning it to benefit from emerging regulatory reforms and patient access programs.
Founded through the combination of Atlas Biotechnologies and InterHealth Nutraceuticals, Zenabis leverages a management team with deep experience in agriculture, pharmaceutical manufacturing and international trade. Chief Executive Officer Sahba Sobhani leads the company’s strategic direction, supported by executives with backgrounds in regulatory affairs, quality assurance and clinical research. With a focus on operational efficiency and product innovation, Zenabis aims to carve out a differentiated position in the highly competitive cannabis sector.
AI Generated. May Contain Errors.
